Karus Therapeutics Strengthens Clinical Leadership Team with Appointment of Dr Hilary McElwaine-Johnn, MD as Chief Medical Officer

Oxfordshire, UK, 17 July 2019 – Karus Therapeutics Ltd (‘Karus’), a clinical-stage biopharmaceutical company developing precision medicines for cancer, today announced the appointment of Dr Hilary McElwaine-Johnn, MD as Chief Medical Officer (CMO) with immediate effect. Dr McElwaine-Johnn is a Physician with over 25 years’ experience in drug development, most recently as CMO at cancer gene […]

2018 Operational Update

Tim Edwards appointed as Executive Chairman KA2237 and KA2507 – innovative, molecular-targeted anti-cancer therapeutics – progressing in Phase I clinical trials for the treatment of cancer, with clinical responses confirmed for KA2237 in patients with refractory B-cell lymphomas Research and development activities on a novel, differentiated HDAC6 inhibitor series progressing well, with preclinical development candidate […]

Karus Therapeutics Announces First Cancer Patients Dosed with KA2507, a Small Molecule HDAC6-Selective Inhibitor, in a Phase I Clinical Trial

Oxfordshire, UK, 18th September 2017 – Karus Therapeutics Ltd (‘Karus’), a leader in the design and development of innovative medicines with breakthrough potential in the treatment of cancer, today announced that the first patients have been dosed with its histone deacetylase 6 (HDAC6) inhibitor, KA2507, in a Phase I clinical study. This is the Company’s second […]

Karus Therapeutics presenting at the CHI DoT 11th Annual Next-Generation Histone Deacetylase Inhibitors conference

Oxford, UK, 4 August 2017 – Karus Therapeutics Ltd, a leader in the development of innovative medicines for the treatment of cancer, has announced its COO/CSO will be delivering two presentations at the CHI DoT 11th Annual Kinase Inhibitor Discovery conference, Boston, 27 and 28 September 2017. The presentation on Wednesday 27 September by Stephen […]

Karus Therapeutics presenting at the 18th Annual Drug Discovery Summit/5th Annual Discovery Chemistry & Drug Design

Oxford, UK, 1 May 2017 – Karus Therapeutics Ltd, a leader in the development of innovative medicines for the treatment of cancer, has announced its Chief Scientific Officer will be delivering a presentation at the 18th Annual Drug Discovery Summit/5th Annual Discovery Chemistry & Drug Design Congress, Berlin, 13 June 2017. Stephen Shuttleworth, COO & […]

Karus Therapeutics presenting at BIO-Europe

Oxford, UK, 21 October 2016 – Karus Therapeutics Ltd, a leader in the development of innovative medicines for the treatment of cancer, has announced its CEO will be delivering a presentation at the 22nd BIO-Europe, Cologne, Germany, 7-9 November 2016. Dr Simon Kerry, Karus’s CEO, will be presenting on the Oncology track, taking place in the […]

Karus Therapeutics Announces First Lymphoma Patients Dosed with KA2237 in Clinical Study at the MD Anderson Cancer Center

First cohort of cancer patients has been dosed with Karus’s lead candidate, KA2237 Potential first-in-class dual-PI3K-p110β/δ inhibitor with broad potential to treat hematological and solid tumors KA2237 combines an immunotherapeutic response and a direct effect on tumor growth Oxford, UK, 5 October 2016 – Karus Therapeutics (‘Karus’), a leader in the development of innovative, orally-active […]

Karus Therapeutics giving lecture at BIO Investor

Oxford, UK, 3 October 2016 – Karus Therapeutics Ltd, a leader in the development of innovative medicines for the treatment of cancer, has announced its CEO will be delivering a lecture at the 15th Annual BIO Investor Forum, San Francisco, California, USA, 18-19 October 2016. Dr Simon Kerry, Karus’s CEO, will be lecturing on oncology as […]

Karus Therapeutics giving lecture at 10th Annual Symposium – Next Generation Histone Deacetylase Inhibitors

Oxford, UK, 7 September 2016 – Karus Therapeutics, a leader in the development of innovative medicines for the treatment of cancer, has announced its CSO will be attending and delivering a lecture at the 9th Annual Kinase Inhibitor Discovery conference, Boston, USA, 19 September 2016. Stephen Shuttleworth, Karus’s CSO, will be lecturing in the session Role […]

Karus Therapeutics delivering lecture at 9th Annual Kinase Inhibitor Discovery conference

Oxford, UK, 1 September 2016 – Karus Therapeutics, a leader in the development of innovative medicines for the treatment of cancer, has announced its CSO will be attending and giving a lecture at the 9th Annual Kinase Inhibitor Discovery conference, Boston, USA, 21-22 September 2016. Stephen Shuttleworth, Karus’s CSO, will be lecturing in the session Kinase […]